From Setbacks to Stepping Stones

Washington, D.C. (September 13, 2012)— The Pharmaceutical Research and Manufacturers of America (PhRMA) released two new reports at its first annual Research and Hope Awards ceremony, which celebrated advancements made in research and patient care for Alzheimer’s disease.  The reports detail how obstacles play a role in moving Alzheimer’s research forward, as well as the progress that is being made to help confront this complicated disease. 

Researching Alzheimer's Medicines: Setbacks and Stepping Stones

New Medicines Yield Significant Progress against Serious Diseases

PhRMA Statement on Flawed British Medical Journal Analysis

Washington, D.C. (August 9, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on the recent analysis in the British Medical Journal:

Infographic: Building a 21st Century Workforce

Selected Medicines in Development for Mental Illness

Anxiety (Social Phobia) – Anxiety disorders affect more than 40 million adults in the U.S., with about 15 million of those suffering from acute social phobia, according to the National Institute of Mental Health.  A potential medicine in development is part of a new class of psychotropic pherines.  The drug, which has a unique mechanism of action, is administered in an intranasal spray and acts with rapid-onset on peripheral receptors from nasal chemosensory neurons that act on the hypothalamic-limbic system in the brain, which is thought to be the primary center of emotion

Medicines in Development for Mental Illnesses - 2012 Report

PhRMA Statement on Patent Reform - 2011

Washington, D.C. (June 23, 2011) — The Pharmaceutical Research and Manufacturers of America Deputy Vice President Karl Uhlendorf today released the following statement regarding patent reform:

Cumulative Gains Are Building Blocks to Incredible Progress in War Against Cancer

Washington, D.C. (June 12, 2012) — Following Food and Drug Administration (FDA) approval of a new cancer medicine, it often takes years of additional research to fully understand the value of the medicine to patients, according to "Recognizing Value in Oncology Innovation," a new paper released by the Boston Healthcare Associates (BHA).

Recognizing Value in Oncology Innovation Report


Subscribe to RSS - Innovation